DPP-4 inhibitors and SGLT2 inhibitors effective in diabetics after kidney transplant

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-12-26 07:00 GMT | Update On 2020-12-26 10:08 GMT

Greece:Evidence regarding the utilization of DPP-4 inhibitors and particularly SGLT2 inhibitors and GLP-1 receptor agonists is limited in renal transplant recipients (RTRs).

Incretin based therapies DPP-4 inhibitors and SGLT2 inhibitors are both safe and effective in recipients of kidney transplant, suggests a recent study published in the journal Diabetes Research and Clinical Practice.

There is a limited evidence on the use of DPP-4 inhibitors and particularly SGLT2 inhibitors and GLP-1 receptor agonists in renal transplant recipients (RTRs). Dora Oikonomaki, Evaggelismos General Hospital, Athens, Greece, and colleagues therefore, aimed to conduct a systematic review and meta-analysis regarding the utility of incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists as well as sodium-glucose co-transporter-2 (SGLT2) inhibitors in people with posttransplantation diabetes mellitus (PTDM).

For the purpose, the researchers searched the online databases for publications on Kidney/Renal Transplantation and DPP-4 inhibitors, GLP-1-receptor agonists and SGLT-2 inhibitors. It included studies that in which these antidiabetics were used.

Overall, sixteen studies and 310 people were included in the analysis.

Key findings of the study include:

Participants received DPP-4 inhibitors in 8 studies, SGLT-2 inhibitors in 6 studies and GLP-1 receptor agonists in 2 studies, with a mean follow-up of 22.03 ± 14.95 weeks.
Hemoglobin A1c (HbA1c) reduction was demonstrated in 10 studies (mean +/- standard deviation (MD) = - 0.38 %).
MD of HbA1c was -0.3741 and -0.4596 mg/dl for DPP-4 inhibitors and SGLT-2 inhibitors respectively. Nine studies demonstrated differences in fasting plasma glucose (FPG) (MD = – 25,76) and 5 studies in post-prandial glucose (PPG) (MD = – 6.61) before and following treatment.
Most studies did not show adverse effects on the glomerular filtration rate (GFR) and hepatic function.

"DPP-4 inhibitors and SGLT2 inhibitors appear both efficacious and safe in renal transplant recipients. More high-quality studies are required to guide therapeutic choices for PTDM," wrote the authors.

The study, "Incretin-Based Therapies and SGLT-2 Inhibitors in Kidney Transplant Recipients With Diabetes," is published in the journal Diabetes Research and Clinical Practice.

DOI: https://doi.org/10.1016/j.diabres.2020.108604

Article Source : Diabetes Research and Clinical Practice

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

DPP-4 inhibitors and SGLT2 inhibitors effective in diabetics after kidney transplant

Similar News

Sanofi Tzield approved in China for adult, pediatric patients with stage 2 type 1 diabetes

Dapagliflozin and Empagliflozin Shows Comparable Effectiveness in Type 2 Diabetes: Study

Coronary Microvascular Dysfunction Increases Risk of Heart Events in Diabetic Patients: Study

Breathing device could have profound impact on survival for people with sleep apnoea and type 2 diabetes

Early Metabolic Patterns in Prediabetes Help Predict Long-Term Complications: Study

EMA warns of sharp rise in illegal medicines sold in EU

Glipizide and Metformin FDC - Effective, Safe and Cost-Effective in T2D: Latest Indian Real-World Study

Enavogliflozin Improves Adipokine Profile and Metabolic Health in T2DM: Study